wada 2025 prohibited list bpc-157 tb-500 World Anti-Doping Agency (WADA) Prohibited
Description
Cloudiness can indicate: Protein aggregation (the tirzepatide peptide clumping together) Microbial contamination Chemical degradation Incompatibility between ingredients Any of these situations makes the medication potentially unsafe
Intended Use: For laboratory research use only Key Characteristics of GLOW GHK-CU / BPC-157 / TB500 Multi-peptide research blend combining three structurally distinct peptides
Who should not rely on BPC-157 for alcohol protection: Anyone with diagnosed liver disease (cirrhosis, hepatitis, fatty liver disease) People with alcohol use disorder who need medical treatment, not peptide supplementation Anyone taking hepatotoxic medications (acetaminophen at high doses, certain statins, methotrexate) Individuals with bleeding disorders or on anticoagulants BPC-157 is not a substitute for medical care
This language pattern appears repeatedly in sites that received warning letters
intraperitoneal and others, in order to establish the effects and make the results more reliable
